Búsqueda avanzada

La Sra. Mardi C. Dier es directora financiera y vicepresidenta ejecutiva de Ultragenyx Pharmaceutical, Inc., directora independiente de Oric Pharmaceuticals, Inc. y directora independiente de Adamas Pharmaceuticals, Inc. Forma parte del Consejo de Administración de Prelude Therapeutics, Inc. y de Oric Pharmaceuticals, Inc. y Adamas Pharmaceuticals, Inc. La Sra. Dier trabajó anteriormente como directora financiera, directora comercial y vicepresidenta ejecutiva de Portola Pharmaceuticals, Inc., vicepresidenta de relaciones con los inversores de Chiron Corp., directora de banca de inversiones de Prudential Equity Group LLC, contable senior de KPMG LLP, contable senior de KPMG Peat Marwick LLP y directora de banca de inversiones de Prudential Securities. También formó parte del consejo de administración de Jewish Vocational Service, Inc. y de Futures Strategic Trust. Se licenció en la Universidad de Stanford y obtuvo un MBA en la Anderson School of Management de la UCLA.

Gregory Dier worked as an Associate Research Analyst at Hartford Investment Management Co..
Mr. Dier attended Middlebury College, where he received an undergraduate degree in 2013.

James G.
Dier, who previously worked at Thrivent Investment Management, Inc., held the position of Director.

Louise Dier served as an Independent Non-Executive Director at TClarke Plc from 2019 to 2022.
Prior to that, she worked as a Managing Director at David Chipperfield Architects Ltd., General Manager-United Kingdom at DO & CO Catering-Consult & Beteiligungs GmbH, and Head-Human Resources at IMG Europe Ltd.
She graduated from the University of Cambridge.

Martina Dier has a current job as the Director of Global Communications at TeamViewer SE.